Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.69 |
| ▸ | PKM | P14618 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522281 | 0.94 | LMNA (0.71) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL19078974 | 0.87 | ALDH1A1 (0.69) | ALDH1A1PKMLMNAHTTCA12 | |
| SCHEMBL13223680 | 0.87 | ALDH1A1 (0.69) | ALDH1A1PKMLMNAHTTCA12 | |
| SCHEMBL31522337 | 0.86 | ALDH1A1 (0.57) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL9871136 | 0.86 | MEN1 (0.59) | ALDH1A1PKMMEN1KMT2ALMNA | |
| SCHEMBL15797966 | 0.86 | ALDH1A1 (0.65) | ALDH1A1PKMLMNAHDAC1TBXA2R | |
| SCHEMBL1403259 | 0.86 | ALDH1A1 (0.73) | ALDH1A1PKMLMNAHDAC1HDAC3 | |
| SCHEMBL31522327 | 0.86 | ALDH1A1 (0.73) | ALDH1A1PKMLMNAHDAC1HDAC3 | |
| SCHEMBL31522332 | 0.86 | ALDH1A1 (0.73) | ALDH1A1PKMLMNAHDAC1HDAC3 | |
| SCHEMBL9871596 | 0.84 | LMNA (0.88) | ALDH1A1PKMMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796664-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2330894-B1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORP (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION | 2016-05-05 | — | — | US | disclosed |
| US-9265734-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | REPLIGEN CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010028192-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | HDAC1, HDAC5, HDAC2 | ALDH1A1 194/4885PKM 2101/4885MEN1 3987/4885 |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | HDAC1, HDAC5, HDAC2 | ALDH1A1 194/4885PKM 2101/4885MEN1 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.